Clearview Wealth Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Clearview Wealth Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300	Closed	-$1K	–	750
2021 Q3	$1K	Hold	300	–	–	﹤0.01%	645
2021 Q2	$2K	Hold	300	–	–	﹤0.01%	598
2021 Q1	$1K	Hold	300	–	–	﹤0.01%	602
2020 Q4	$1K	Buy	+300	New	+$1.28K	﹤0.01%	562

Clearview Wealth Advisors's ADMS Position: Q4 2021 in Review

Clearview Wealth Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 300 shares — an estimated $1K sold.

Clearview Wealth Advisors first reported a position in ADMS in Q4 2020 and held it in 4 quarters. The position peaked at $2K in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Clearview Wealth Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Clearview Wealth Advisors sold 300 Adamas Pharmaceuticals shares in Q4 2021, an estimated $1K.
Clearview Wealth Advisors first reported a position in Adamas Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Clearview Wealth Advisors's Adamas Pharmaceuticals position peaked at $2K in Q2 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Clearview Wealth Advisors's 13F filing for Q4 2021, filed 2 Feb 2022.